Document is current
Any future updates will be listed below
-
Authors
Smyth, Laura J. https://orcid.org/0000-0001-6419-4826
Dahlström, Emma H. https://orcid.org/0000-0003-1271-8696
Syreeni, Anna https://orcid.org/0000-0003-1857-2560
Kerr, Katie
Kilner, Jill https://orcid.org/0000-0002-6020-4617
Doyle, Ross
Brennan, Eoin https://orcid.org/0000-0003-4908-5474
Nair, Viji
Fermin, Damian
Nelson, Robert G.
Looker, Helen C.
Wooster, Christopher https://orcid.org/0000-0002-0321-9556
Andrews, Darrell
Anderson, Kerry
McKay, Gareth J.
Cole, Joanne B. https://orcid.org/0000-0001-9520-2788
Salem, Rany M. https://orcid.org/0000-0001-8816-6862
Conlon, Peter J.
Kretzler, Matthias https://orcid.org/0000-0003-4064-0582
Hirschhorn, Joel N.
Sadlier, Denise
Godson, Catherine
Florez, Jose C. https://orcid.org/0000-0002-1730-9325
,
Forsblom, Carol https://orcid.org/0000-0002-3354-7454
Maxwell, Alexander P. https://orcid.org/0000-0002-6110-7253
Groop, Per-Henrik https://orcid.org/0000-0003-4055-6954
Sandholm, Niina https://orcid.org/0000-0003-4322-6942
McKnight, Amy Jayne https://orcid.org/0000-0002-7482-709X
- License Information
-
More Information
Article History
Received: 27 April 2022
Accepted: 14 November 2022
First Online: 22 December 2022
Competing interests
: P.-H.G has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice and Sanofi. J.C.F. has received consulting honoraria from Goldfinch Bio and AstraZeneca, and speaker fees from Novo Nordisk, AstraZeneca, and Merck for research lectures over which the author had full control of content. J.N.H. hold equity in Camp4 Therapeutics. Dr. M. Kretzler reports grants and contracts outside the submitted work through the University of Michigan with NIH, Chan Zuckerberg Initiative, JDRF, AstraZeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Janssen, Boehringer-Ingelheim, Moderna, European Union Innovative Medicine Initiative, Certa, Chinook, amfAR, Angion, RenalytixAI, Travere, Regeneron, IONIS; consulting fees through the University of Michigan from Astellas, Poxel and Janssen; and a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed. R.M.S. receives funding from Travere Therapeutics. The funders listed had no role in any part of this study (design, data collection, management, analysis, interpretation, preparation, review or approval of the manuscript). The remaining authors declare no competing interests.
